Project Grant R21AG100975
Award Date 9/1/26
Completion Date 8/31/28
Dollars Obligated $428K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
- The National Institute on Aging awarded the University of Massachusetts Medical School $419,946 on September 1, 2026, under the Aging Research program (CFDA 93.866) for research into RNA interference-mediated modulation of apolipoprotein E, innate immune response, and tau pathology as a disease-modifying treatment for Alzheimer's disease. The funded research develops and tests small interfering RNA scaffolds that simultaneously target multiple genes implicated in Alzheimer's disease progression....
- The National Institute on Aging awarded The Johns Hopkins University $653,100 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate poly(ADP-ribose) polymerase 1 (PARP1) and macrophage migration inhibitory factor (MIF) nuclease activity in tau-related neurodegeneration and cognitive dysfunction. The research will examine neurobehavior and neuropathology in PS19 transgenic mice models with PARP1 knockout and MIF nuclease-deficient or tautomerase-deficient genetic...
- The National Institute on Aging awarded the University of Virginia $583,815 on August 15, 2026, under the Aging Research program (CFDA 93.866) to support research into oligodendrocyte lineage dysfunction during aging and Alzheimer's disease. The project aims to understand how myelin loss—a pathology common to both aging and Alzheimer's disease—develops in the central nervous system and to identify therapeutic targets for cognitive impairment. The research focuses on oligodendrocyte precursor...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded Emory University $657,222 in Project Grant R01AG093923 on February 15, 2026, under the Aging Research program (CFDA 93.866). The award funds research into the amyloid scaffold hypothesis in Alzheimer's disease. The project investigates how proteins co-accumulate with amyloid-beta in diseased brains, testing whether this protein scaffolding—rather than direct amyloid toxicity—drives pathophysiology in...
- The National Institute on Aging awarded Artery Therapeutics, Inc. a $2.644 million Cooperative Agreement on February 15, 2026, under the Aging Research program (CFDA 93.866) to conduct two sequential clinical studies of CS6253, an ABCA1 agonist candidate for hereditary APOE4-associated dementia and mild cognitive impairment. The first study is a subcutaneous pharmacokinetic feasibility study designed to demonstrate that multiple-fold higher drug exposure levels can be achieved via subcutaneous...
- The National Institute on Aging awarded $1,212,742 to the Sloan-Kettering Institute for Cancer Research on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate epichaperomes as a mechanism for restoring drug responsiveness in Alzheimer's disease. The research tests the hypothesis that epichaperome inhibition with PU-AD restores synaptic architecture and re-enables responsiveness to levetiracetam (LEV), a therapy whose efficacy depends on properly localized SV2A...
- The National Institute on Aging awarded The Jackson Laboratory $716,579 on December 15, 2025, under the Aging Research program (CFDA 93.866) to conduct genetic dissection of microglia functions in complement-mediated synapse loss in Alzheimer's disease. The award funds basic neuroscience research examining how microglia—the brain's resident macrophages—trigger neuronal synapse loss through complement cascade activation in Alzheimer's disease models. The project addresses three knowledge gaps:...
- The National Institute on Aging awarded The Johns Hopkins University $581,090 under the Aging Research program (CFDA 93.866) on September 1, 2026, to conduct the Joint Environment & Occupation Dementia Study (JEODE), a longitudinal investigation of combined environmental and occupational exposures as risk factors for Alzheimer's disease and related dementias and cognitive decline. The study uses data from the National Health and Aging Trends Study, a nationwide cohort of 9,204 Medicare...
- The National Institute on Aging, a division of the Department of Health and Human Services National Institutes of Health, awarded Advantage Therapeutics, Inc. $3.749 million on September 20, 2025, under the Aging Research program (CFDA 93.866) to perform IND-enabling studies on a small-molecule immunomodulating compound for Alzheimer's disease. The recipient will conduct preclinical and IND-enabling studies on a disease-modifying therapeutic designed to reduce brain inflammation and restore...
- The National Institute on Aging awarded $1.602 million to J. David Gladstone Institutes on February 15, 2026, under the Aging Research program (CFDA 93.866) to investigate how the APOE4 genetic allele disrupts brain energy metabolism in Alzheimer's disease. Work is performed in San Francisco, California through January 31, 2031. The award funds research using live imaging and mass spectrometry to measure metabolic fluxes in mouse models and magnetic resonance spectroscopic imaging to assess...